Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have received an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $8.00.

Several analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Monday, December 29th. Bank of America lifted their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Morgan Stanley reissued an “overweight” rating and set a $12.00 target price on shares of Sana Biotechnology in a research report on Friday, March 13th. Finally, HC Wainwright lowered their target price on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, March 4th.

Institutional Trading of Sana Biotechnology

A number of institutional investors have recently made changes to their positions in SANA. Baillie Gifford & Co. increased its position in Sana Biotechnology by 13.6% during the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after buying an additional 1,371,775 shares in the last quarter. Vanguard Group Inc. raised its stake in Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after buying an additional 1,517,474 shares during the last quarter. State Street Corp boosted its holdings in Sana Biotechnology by 20.6% in the fourth quarter. State Street Corp now owns 8,054,841 shares of the company’s stock worth $32,783,000 after acquiring an additional 1,374,300 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Sana Biotechnology by 20.3% in the fourth quarter. Geode Capital Management LLC now owns 4,118,138 shares of the company’s stock worth $16,763,000 after acquiring an additional 694,606 shares in the last quarter. Finally, Marex Group plc purchased a new stake in shares of Sana Biotechnology during the second quarter worth about $10,423,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Trading Down 3.2%

SANA opened at $2.68 on Tuesday. The firm has a market cap of $715.21 million, a price-to-earnings ratio of -2.76 and a beta of 1.96. Sana Biotechnology has a 12 month low of $1.26 and a 12 month high of $6.55. The stock has a fifty day moving average price of $3.83 and a 200-day moving average price of $4.14.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). On average, equities research analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.